1/17/2006
Media Contact:
Jenny Siminski, BioCrossroads
(317) 238-2456 (office) (317) 213-5466 (mobile)jsiminski@biocrossroads.com |
 |
BioCrossroads and Indiana Future Fund to celebrate formation and $16.5 million investment in new life sciences company
Deal marks largest early-stage biotech investment in Indiana in at least 10 years.
INDIANAPOLIS: In what is considered to be a historic moment in the history of the BioCrossroads initiative and the Indiana Future Fund, officials will gather at the Skyline Club in Indianapolis on Tuesday to celebrate the formation of a new $16.5 million Indianapolis-based biopharmaceutical company called CoLucid.
With seven out of every 10 new jobs in the U.S. created by small, entrepreneurial companies, BioCrossroads is focused on creating new businesses from existing life sciences assets in Indiana. This ‘21st Century’ economic development strategy relies on our ability to harness ideas, talent and money to grow small businesses and our economy. The formation of CoLucid is a great example of how BioCrossroads is leveraging these resources to create jobs and opportunity for Hoosiers.
WHAT: Media availability with officials involved in the formation of a new $16.5 million biopharmaceutical company
WHEN: Tuesday, January 17, 2006 at 11:30 a.m.
WHERE: Skyline Club (36th Floor of the OneAmerica Building)
WHO: Indianapolis Mayor Bart Peterson, BioCrossroads Chairman of the Board Dr. August Watanbe, BioCrossroads President and CEO David Johnson, Eli Lilly and Company Vice President of Corporate Business Development for Lilly and Chairman of the Indiana Future Fund Advisory Board Chairman Josh Salisbury, Credit Suisse Managing Director Michael Arpey, venture capital firm representatives involved in CoLucid, legislators, business leaders
Officials with bolded names will be providing formal comments. In addition, David Johnson and IU President Adam Herbert will provide overviews of their respective organizations.
|
